– Conference Call and Webcast to Follow at 5:00 p.m. EST/ 2:00 p.m.
PST –
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Feb. 8, 2018--
Exelixis,
Inc. (NASDAQ: EXEL) announced today that its fourth quarter and full
year 2017 financial results will be released on Monday, February 26,
2018 after the markets close. At 5:00 p.m. EST / 2:00 p.m. PST, Exelixis
management will host a conference call and webcast to discuss the
results and provide a general business update. Access to the event is
available via the Internet from the company’s website.
To access the webcast link, log onto www.exelixis.com
and proceed to the News & Events / Event Calendar page under the
Investors & Media heading. Please connect to the company’s website at
least 15 minutes prior to the conference call to ensure adequate time
for any software download that may be required to listen to the webcast.
Alternatively, please call 855-793-2457 (domestic) or 631-485-4921
(international) and provide the conference call passcode 6857848 to join
by phone.
A telephone replay will be available until 8:00 p.m. EST on February 28,
2018. Access numbers for the telephone replay are: 855-859-2056
(domestic) and 404-537-3406 (international); the passcode is 6857848. A
webcast replay will also be archived on www.exelixis.com
for one year.
About Exelixis
Founded in 1994, Exelixis, Inc. (NASDAQ: EXEL) is a commercially
successful, oncology-focused biotechnology company that strives to
accelerate the discovery, development and commercialization of new
medicines for difficult-to-treat cancers. Following early work in model
genetic systems, we established a broad drug discovery and development
platform that has served as the foundation for our continued efforts to
bring new cancer therapies to patients in need. We discovered our lead
compounds, cabozantinib and cobimetinib, and advanced them into clinical
development before entering into partnerships with leading
biopharmaceutical companies in our efforts to bring these medicines to
patients globally. We are steadfast in our commitment to prudently
reinvest in our business to maximize the potential of our pipeline. We
intend to supplement our existing therapeutic assets with targeted
business development activities and internal drug discovery – all to
deliver the next generation of Exelixis medicines and help patients
recover stronger and live longer. Exelixis recently earned a spot on
Deloitte’s Technology Fast 500 list, a yearly award program honoring the
500 fastest-growing companies over the past four years. For more
information about Exelixis, please visit www.exelixis.com
or follow @ExelixisInc on Twitter.
Exelixis and the Exelixis logo are registered U.S. trademarks.
View source version on businesswire.com: http://www.businesswire.com/news/home/20180208006341/en/
Source: Exelixis, Inc.
Exelixis, Inc.
Susan Hubbard, 650-837-8194
Executive
Vice President,
Public Affairs & Investor Relations
shubbard@exelixis.com
